	US 12,270,080 B2
	NcRNA and uses thereof
Arul Chinnaiyan, Plymouth, MI (US); John Prensner, Ann Arbor, MI (US); and Matthew Iyer, Ann Arbor, MI (US)
Assigned to THE REGENTS OF THE UNIVERSITY OF MICHIGAN, Ann Arbor, MI (US)
Filed by THE REGENTS OF THE UNIVERSITY OF MICHIGAN, Ann Arbor, MI (US)
Filed on Jul. 26, 2019, as Appl. No. 16/523,008.
Application 16/523,008 is a continuation of application No. 15/156,936, filed on May 17, 2016, granted, now 10,407,735, issued on Sep. 10, 2019.
Application 15/156,936 is a continuation of application No. 13/797,106, filed on Mar. 12, 2013, abandoned.
Application 13/797,106 is a continuation in part of application No. 13/299,000, filed on Nov. 17, 2011, abandoned.
Claims priority of provisional application 61/415,490, filed on Nov. 19, 2010.
Prior Publication US 2020/0224276 A1, Jul. 16, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/68 (2018.01); A61K 31/4184 (2006.01); C12Q 1/6886 (2018.01)

CPC C12Q 1/6886 (2013.01) [A61K 31/4184 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/112 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/136 (2013.01); C12Q 2600/158 (2013.01)]

7 Claims

1. A method for treating prostate cancer in a subject, said method comprising:

(a) processing a sample from the subject to isolate from the sample or to enrich the sample in non-coding RNA (ncRNA)

(b) detecting an increased level of expression of PCAT-14 ncRNA in said sample compared to a pre-established threshold level, wherein the detecting comprises sequencing, nucleic acid hybridization or nucleic acid amplification, and wherein the PCAT-14 ncRNA has the sequence of any one of SEQ ID NOs: 3-9;

(d) administering an effective amount of an anti-prostate cancer therapeutic, a chemotherapy, a radiation therapy, an immunotherapy/biological therapy, or a photodynamic therapy to the subject prognosed as likely having prostate cancer.